Liminatus Pharma LLC

Iris Acquisition Corp (Nasdaq: IRAA), sponsored by Liminatus Pharma LLC, was a blank-check company that went public in 2022 with a stated focus on the biotech and pharmaceutical sector. The SPAC announced its definitive business combination agreement in December 2022, targeting a life sciences target. The transaction has since closed, and IRAA is recorded as a completed deal in the broader SPAC market. Liminatus Pharma LLC served as the sponsor entity throughout the vehicle's lifecycle, from initial public offering through deal completion. For the complete filing history, deal timeline, and comparable transaction data on Iris Acquisition Corp, create a free account at SpacDesk.

SPAC Counterparty (1)